Dicerna Pharma (DRNA) Misses Q2 EPS by 94c

Dicerna Pharma (NASDAQ: DRNA) reported Q2 EPS of ($0.53), $0.94 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $41.3 million versus the consensus estimate of $91.29 million.

For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Movano (MOVE) Misses Q2 EPS by 195c